Esteve purchases UQUIFA API manufacturing facility in Barcelona

Matt Dixon • Feb 04, 2022

Esteve Química purchases one of the UQUIFA Group's two pharmaceutical fine chemicals plants in Barcelona. 

About UQUIFA 

UQUIFA is a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates for the pharmaceutical and animal health industries globally.


The LLiçà de Vall site occupies a surface area of 21,176 m2, a workforce of 89 people, and a production capacity of 160 m3 of reaction volume. It currently produces advanced intermediates and active pharmaceutical ingredients, which are exported to Europe, the United States, Latin America and Asia.


The facility meets Good Manufacturing Practices (GMPs) and holds the corresponding AEMPS (Spanish Health Agency) certification, as well as ISO14001:2005 certification covering environmental aspects. It is also audited by several international regulatory authorities such as the Korean FDA and the Japanese PMDA.

About Esteve

Esteve is a Spanish international pharmaceutical company headquartered in Barcelona. The company operates as a collection of organizations that span various areas related to healthcare. This includes Esteve Química; Esteve Pharmaceuticals; ISDIN (skin care), an alliance between ESTEVE and the PUIG Group; and Esteve Teijin Healthcare (ETH) in the field of home respiratory therapy with the Japanese group Teijin Pharma.

CCD Partners’ role

CCD Partners’ Matt Dixon, Peter Dixon, and Matthew Wise advised UQUIFA on this carve-out and divestment project. The project began with an initial scoping and strategic review phase, before launching a formal divestment process with a number of interested parties, and driving the project through due diligence to completion.

Staffan Schüberg, CEO of ESTEVE, commented:


''This operation is an excellent opportunity to increase our industrial capacity and serve our customers and patients worldwide, to improve people's health and be true to our purpose. We are advancing towards our vision of becoming an international proprietary specialty pharma and with this opportunity we will be able to expand our services to the global specialty pharma market''.


Matt Dixon, Managing Partner at CCD Partners, commented:

“We were engaged to find a new home for one of UQUIFA’s Spanish sites. I’m pleased to say we introduced several parties with strong interest and strategic rationale in acquiring the site and conducted a private auction process before settling on the best new owner, Esteve Quimica.”

 Saurabh Gurnurkar, Managing Director of UQUIFA Sciences, commented:


"The UQUIFA team is pleased that the LLiçà de Vall site will get a committed owner with the capacity to develop it to its full potential. This divestment will help UQUIFA streamline our Spanish operations in line with our strategic goals and better align with our customers' evolving needs.


My thanks to everyone on the CCD Partners team for getting this deal to the finish line. It was a pleasure working with each of you every step of the way, from the initial scoping exercise all the way through to final execution.”


CCD Partners is a consultancy specialised in corporate transformations in small and mid-market chemicals and life sciences businesses.

To organise a call with one of our partners please email contact@ccdpartners.com

Receive M&A news relevant to your business

At critical moments our clients engage us to provide pre-publicity "off-market" intelligence to give them the edge over the competition - we also provide up-to-the-minute public or "on-market" intelligence for free

Contact Us

We're committed to your privacy. CCD Partners uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe at any time. For more information, please see our Privacy Policy.   

RECENT POSTS

By Matt Dixon 05 Dec, 2022
Market leading provider of formulated chemical process aids and foam control, PennWhite has been acquired by Manali Petrochemicals, part of the AM International Holdings group.
By Matt Dixon 02 Dec, 2022
Global source of industrial gas news, views, and debate, gas world has been sold by John and Karen Raquet to the senior management team in an MBO, backed by Mobeus Equity Partners.
By Matt Dixon 13 Sep, 2022
Polyblend UK Ltd is one of the market leaders in PVC based polymers. We are experts in manufacturing a comprehensive range of liquid plastisol and dispersion systems, complemented by our Speciality Distribution business supplying plasticisers, resins and PVC additives.
By Matt Dixon 05 May, 2022
GFBiochemicals is a sustainable chemicals company that produces levulinic acid derivatives at commercial scale directly from biomass. Having perfected its technology, product, and certification, the company is entering a new phase of commercialization.
By CCD Partners 20 Apr, 2022
In the latest episode of the Chemical Transformations podcast , CCD Partners' Managing Partner Matt Dixon speaks with Ted Clark, former President and CEO of Royal Adhesives & Sealants, discussing his new book "Shipping Clerk to CEO: The Power of Curiosity, Will, and Self Directed Learning”. The book tells the story of Clark’s remarkable career journey from entry-level worker to CEO of a $240m chemical company by the age of 42.
By Matt Dixon 04 Feb, 2022
Specialty materials manufacturer Vertellus has acquired Polyscope Polymers B.V., a global leader in specialty additives for coatings, electronics applications, and engineering polymers.
By Matt Dixon 01 Nov, 2021
Biosynth Carbosynth is a fully hybrid Research Products, Life Sciences Reagents and Custom Synthesis and Manufacturing Services Company with global research, manufacturing and distribution facilities. They are the supplier of choice for many in the pharmaceutical, life science, food, agrochemical, cosmetic and diagnostic sectors and manufacture and source a vast range of chemical and biochemical products.
By CCD Partners 12 Oct, 2021
Steve Allin co-founded Charnwood Molecular with Phil Page in 1998. 22 years later, the business has evolved dramatically from its origins as a spinout of Loughborough University. Backed by a partnership with Synova Capital, the company is now preparing to move into a former AstraZeneca research facility and has already completed its first M&A deal, acquiring Aurelia Bioscience in summer 2021. CCD Partners’ Matt Dixon spoke with Steve about the journey from full-time academia to running a high-growth market leader.
By Matt Dixon 24 Sep, 2021
Aspire was founded in 2009. Aspire has an asset-light business model that focuses on R&D, business development and sales and marketing, while outsourcing manufacturing and distribution to specialist third parties. For more details see www.aspirepharma.co.uk.
By Dr Michelle Lynch 22 Jul, 2021
CCD Partners Senior Advisor Dr Michelle Lynch analyses the net zero roadmaps of five of Europe's leading speciality chemical companies, exploring the details of their strategies and evaluating the real-world impact of their commitments to climate neutrality.
Show More
Share by: